A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of QLS2312 Injection

The requested reference [82d93970c79e4fcce78c938a49d6e19b32cc3cca] no longer exists in our database. It has been replaced by the current reference: [56d9ddcde95f8f3c6ab98f999aec162202111372]

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This study is a first-in-human Phase 1 clinical study conducted in healthy adult participants in China to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of QLS2312 Injection after single and multiple subcutaneous administrations. The study consists of Part A and Part B: Part A is a single-ascending-dose study, and Part B is a multiple-ascending-dose (MAD) study.
Epistemonikos ID: 2d2492e3f912b00c853057b5940052d4b75198e6
First added on: Oct 07, 2026